We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Selenium Supplementation of Patients With Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00212212
Recruitment Status : Terminated (Insufficient funds to complete study.)
First Posted : September 21, 2005
Last Update Posted : March 7, 2012
Information provided by (Responsible Party):

Study Description
Brief Summary:
This study is being conducted to determine if patients with cirrhosis (liver disease) are selenium deficient. The effect of supplementation with two chemical forms of selenium on plasma selenium biomarkers will be determined and correlated with the severity of the liver disease.

Condition or disease Intervention/treatment
Cirrhosis Dietary Supplement: selenium Dietary Supplement: placebo

Detailed Description:

Selenium is an essential nutrient that plays a role in oxidant defense, among other functions. There is much interest in the role selenium may play in several disease processes. It is possible that certain diseases result in selenium deficiency because of the form of selenium taken in the normal diet.

We propose to measure the selenium biomarkers associated with supplemental intakes of 200 or 400 µg of selenium per day in the chemical form selenate, or with supplemental intake of 200 µg selenium as selenomethionine. 144 patients with cirrhosis will be randomized to one of 4 treatment groups, including a placebo. After treatement for 4 weeks, all participants will receive 400 µg of selenium per day as selenate for 4 weeks. Blood will be measured initially and at 4 and 8 weeks. Selenium, selenoprotein P and glutathione peroxidase will be measured in the plasma.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 99 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Diagnostic
Official Title: Human Selenium Nutritional Requirement and Biomarkers in Health and Disease
Study Start Date : March 2006
Primary Completion Date : March 2012
Study Completion Date : March 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: 1
200 µg selenium as selenate
Dietary Supplement: selenium
200 µg selenium as selenate
Experimental: 2
400 µg selenium as selenate
Dietary Supplement: selenium
400 µg selenium as selenate
Experimental: 3
200 µg selenium as selenomethionine
Dietary Supplement: selenium
200 µg selenium as selenomethionine
Placebo Comparator: 4
placebo tablet
Dietary Supplement: placebo
placebo tablet

Outcome Measures

Primary Outcome Measures :
  1. Plasma selenium biomarkers [ Time Frame: 4 and 8 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adults with cirrhosis

Exclusion Criteria:

  • Pregnancy or planning a pregnancy
  • Selenium supplements of 25 µg or more within the past year
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00212212

United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigator: Raymond F Burk, M.D. Vanderbilt University
More Information

Responsible Party: RBurk, M.D., Vanderbilt University
ClinicalTrials.gov Identifier: NCT00212212     History of Changes
Other Study ID Numbers: DK58763
R01DK058763 ( U.S. NIH Grant/Contract )
R01DK058763-06 ( U.S. NIH Grant/Contract )
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: March 7, 2012
Last Verified: March 2012

Keywords provided by RBurk, Vanderbilt University:
selenium supplements
plasma selenium concentration
plasma glutathione peroxidase
selenoprotein P

Additional relevant MeSH terms:
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Selenic Acid
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Trace Elements
Growth Substances